Healthcare: valuation, profitability, growth and balance sheets
At the close of October 30, 2026, the 58 Healthcare companies with trailing earnings were worth $6.78T together, 39.0 times their last four reported quarters of net income, against 25.8 for all covered companies; the sector’s own median since 2010 is 22.9, and its median company trades at 30.1. In Q2 2026 the sector kept 4.9% of revenue as net income, grew revenue +7.0% on the year and carried net debt of 1.65 times its trailing EBITDA.
The sector read as one company: sums over its members for every ratio, the median company beside them. Weekly valuation since 2010, quarterly margins, growth and balance sheets since 2009; each chart the sector’s own line with its median since the start dashed, and Health Care sector ETF (XLV) in grey on the right-hand axis from the day it was listed. The newest period is drawn hollow while it is still being reported.
Valuation
Price to earnings · market value over trailing twelve months of net income, weekly
The sum of the sector’s market values over the sum of its trailing earnings. Shaded stretches are weeks when the sector’s trailing earnings were a loss in sum, so no multiple exists; the earnings yield below stays defined there, below zero. Readings above 100 leave a gap.
Earnings yield · trailing earnings over market value, percent; negative when the sector lost money in sum
The ten-year Treasury paid 4.9% in the latest week.
Price to sales · market value over trailing twelve months of revenue
Price to book · market value over stockholders' equity
Free cash flow yield · trailing twelve months over market value, percent
REITs and brokers carry no capex line in the extract and are left out.
Dividend yield · trailing twelve months over market value, percent
Profitability
Gross margin · revenue less cost of revenue, percent of revenue, by calendar quarter
Operating margin · percent of revenue
Net margin · percent of revenue
Return on equity · trailing twelve months of net income over stockholders' equity, percent
Return on assets · trailing twelve months of net income over total assets, percent
Growth
Revenue growth · year over year, percent
Earnings growth · net income, year over year, percent; gaps beyond ±100%
Shaded where the sector’s year-ago quarter was a loss in sum, so no growth rate exists.
Share of companies growing revenue · percent of members with revenue up on the year
Balance sheets
Net debt · long-term debt less cash and equivalents, billions of dollars, the sector's members, complete quarters
A member that reports long-term debt only in its 10-K carries that figure through the year. Levels rise partly with coverage in the early years.
Net debt to EBITDA · long-term debt less cash, over trailing operating income plus depreciation and amortization
Debt to equity · long-term debt over stockholders' equity
Share of companies with net cash · more cash and equivalents than long-term debt, percent
The 62 Healthcare companies
Each company at the close of November 2, 2026 and its latest reported quarter, largest first. Margins and growth are the latest quarter’s; the multiples and yields use trailing twelve months. An asterisk marks a company whose share count is the diluted weighted figure because its cover page lists several classes.
| Company | Market value | P/E | P/S | P/B | FCF yield | Dividend yield | Net margin | Revenue growth | Return on equity | Net debt to EBITDA | Quarter |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli LillyLLY | $1.33T | 48.1 | 15.3 | 33.0 | — | 0.5% | 26.4% | +38.6% | 68.5% | — | Q3 FY2026, Sep 30, 2026 |
| Johnson & JohnsonJNJ | $651.3B | 40.5 | 6.6 | 8.0 | 3.2% | — | 0.8% | +5.9% | 19.7% | — | Q3 FY2026, Sep 27, 2026 |
| AbbVieABBV | $510.6B | 80.9 | 7.9 | — | 3.6% | 2.4% | 21.3% | +10.2% | — | — | Q2 FY2026, Jun 30, 2026 |
| MerckMRK | $366.4B | 115.5 | 5.5 | 8.7 | 4.4% | 2.3% | -8.0% | +5.1% | 7.6% | — | Q2 FY2026, Jun 30, 2026 |
| UnitedHealth GroupUNH | $359.4B | 25.4 | 0.8 | 3.4 | 6.6% | 2.3% | 4.9% | +0.4% | 13.5% | 1.58 | Q2 FY2026, Jun 30, 2026 |
| Amgen IncAMGN | $251.6B | 28.8 | 6.6 | 21.5 | 4.0% | 2.1% | 23.6% | +9.5% | 74.8% | — | Q2 FY2026, Jun 30, 2026 |
| Gilead Sciences IncGILD | $211.3B | — | 6.8 | 16.2 | 6.5% | 1.9% | 29.3% | +6.8% | -29.6% | — | Q3 FY2026, Sep 30, 2026 |
| Abbott LaboratoriesABT | $192.1B | 30.6 | 4.3 | 3.7 | 3.8% | 2.2% | 9.7% | +7.8% | 12.1% | — | Q1 FY2026, Mar 31, 2026 |
| Pfizer Inc.PFE | $174.8B | 40.4 | 2.7 | 2.0 | 6.3% | — | -1.6% | +2.6% | 5.1% | — | Q2 FY2026, Jun 28, 2026 |
| Intuitive SurgicalISRG | $151.4B | 51.2 | 13.1 | 9.5 | 2.4% | — | 17.1% | +21.7% | 18.5% | — | Q3 FY2026, Sep 30, 2026 |
| Vertex Pharmaceuticals IncVRTX | $141.7B | 32.2 | 11.3 | 7.0 | 2.7% | — | 33.0% | +12.5% | 21.8% | — | Q2 FY2026, Jun 30, 2026 |
| Bristol-Myers SquibbBMY | $128.8B | 13.9 | 2.6 | 5.5 | 7.2% | 4.0% | 16.5% | +6.9% | 39.5% | — | Q3 FY2026, Sep 30, 2026 |
| Medtronic plcMDT | $127.0B | 24.3 | 3.4 | 2.5 | 4.8% | 2.9% | 15.1% | +13.7% | 10.4% | — | Q1 FY2027, Jul 31, 2026 |
| Stryker CorporationSYK | $116.8B | 32.2 | 4.4 | 5.0 | 3.9% | 1.1% | 11.6% | +7.6% | 15.4% | 1.55 | Q3 FY2026, Sep 30, 2026 |
| McKesson CorporationMCK | $116.4B | 25.4 | 0.3 | — | 5.5% | 0.3% | 0.6% | +7.7% | — | 0.67 | Q1 FY2027, Jun 30, 2026 |
| Regeneron Pharmaceuticals IncREGN* | $101.5B | 21.1 | 6.0 | 3.0 | 3.8% | 0.4% | 38.1% | +36.3% | 14.4% | -0.31 | Q3 FY2026, Sep 30, 2026 |
| HCA Healthcare, Inc.HCA | $97.7B | 14.4 | 1.2 | — | 6.1% | 0.7% | 8.0% | +3.6% | — | — | Q3 FY2026, Sep 30, 2026 |
| 3M CompanyMMM | $92.2B | 26.1 | 3.6 | 22.3 | 2.9% | 1.7% | 20.9% | +1.0% | 85.7% | — | Q3 FY2026, Sep 30, 2026 |
| Elevance Health, Inc.ELV | $89.4B | 17.4 | 0.4 | 2.0 | 7.3% | 1.7% | 2.6% | +1.4% | 11.5% | 2.90 | Q3 FY2026, Sep 30, 2026 |
| ModernaMRNA | $88.2B | — | 39.6 | 13.0 | -1.4% | — | -539.3% | +2.1% | -46.6% | — | Q2 FY2026, Jun 30, 2026 |
| Cigna GroupCI | $78.0B | 12.2 | 0.3 | 1.8 | — | 2.1% | 2.3% | +6.7% | 15.1% | — | Q2 FY2026, Jun 30, 2026 |
| Cencora, Inc.COR | $64.5B | 24.6 | 0.2 | 21.1 | 6.3% | 0.7% | 0.9% | +5.1% | 86.0% | 2.12 | Q3 FY2026, Jun 30, 2026 |
| Boston Scientific Corp.BSX | $64.2B | 17.5 | 3.1 | 2.5 | 5.6% | — | 16.6% | +7.5% | 14.6% | — | Q2 FY2026, Jun 30, 2026 |
| Cardinal Health, Inc.CAH | $59.2B | — | — | — | — | — | — | — | — | — | Q4 FY2026, Jun 30, 2026 |
| NateraNTRA | $54.6B | — | 20.2 | 30.0 | 0.1% | — | -8.9% | +37.7% | -10.6% | — | Q2 FY2026, Jun 30, 2026 |
| Becton, Dickinson and Co.BDX | $54.1B | 57.5 | — | 2.2 | 5.9% | 2.2% | 7.6% | — | 3.9% | — | Q3 FY2026, Jun 30, 2026 |
| Edwards Lifesciences CorpEW | $53.8B | 53.5 | 8.3 | 5.1 | 2.7% | — | 13.9% | +13.6% | 9.5% | -1.43 | Q2 FY2026, Jun 30, 2026 |
| IDEXX LaboratoriesIDXX | $52.9B | 46.4 | 11.6 | 32.8 | 2.4% | — | 27.8% | +9.7% | 70.7% | 0.06 | Q2 FY2026, Jun 30, 2026 |
| Humana Inc.HUM | $49.3B | 43.6 | 0.4 | 2.6 | 2.6% | 0.9% | 3.0% | +23.5% | 6.1% | 2.35 | Q1 FY2026, Mar 31, 2026 |
| Agilent Technologies Inc.A | $48.5B | 33.7 | 6.6 | 6.6 | 2.6% | 0.6% | 19.3% | +8.1% | 19.6% | 0.99 | Q3 FY2026, Jul 31, 2026 |
| Teva Pharmaceutical Industries Limited American Depositary SharesTEVA | $47.4B | 67.2 | — | 6.1 | 2.8% | — | -13.9% | — | 9.1% | — | Q2 FY2026, Jun 30, 2026 |
| Waters CorpWAT | $45.5B | 273.6 | 9.8 | 3.0 | 0.9% | — | -8.3% | +113.3% | 1.1% | — | Q2 FY2026, Jul 4, 2026 |
| IQVIA Holdings Inc.IQV | $42.6B | 30.6 | 2.5 | 6.4 | 4.9% | — | 7.9% | +8.0% | 20.9% | 3.66 | Q3 FY2026, Sep 30, 2026 |
| Revolution Medicines, Inc. Common StockRVMD | $40.3B | — | — | 15.5 | -3.0% | — | — | — | -67.8% | — | Q2 FY2026, Jun 30, 2026 |
| Royalty Pharma plc Class A Ordinary SharesRPRX* | $37.0B | 45.5 | 14.6 | — | — | — | 2.6% | +16.5% | — | — | Q2 FY2026, Jun 30, 2026 |
| Biogen Inc. Common StockBIIB | $36.8B | 105.9 | 3.6 | — | 5.6% | — | -0.7% | +10.6% | — | — | Q3 FY2026, Sep 30, 2026 |
| GE HealthCare TechnologiesGEHC | $36.0B | 16.7 | 1.7 | 3.1 | — | 0.2% | 11.2% | +7.2% | 18.6% | — | Q3 FY2026, Sep 30, 2026 |
| ZOETIS INC.ZTS | $34.4B | 13.1 | 3.6 | 10.9 | 6.7% | — | 28.0% | −0.2% | 83.1% | — | Q2 FY2026, Jun 30, 2026 |
| Illumina IncILMN | $34.3B | 38.3 | 7.5 | 10.9 | 3.1% | — | 19.5% | +4.2% | 28.5% | — | Q3 FY2026, Sep 27, 2026 |
| Mettler-Toledo InternationalMTD | $33.6B | 37.1 | 8.1 | 2622.3 | 2.6% | — | 22.7% | +4.5% | 7062.4% | — | Q2 FY2026, Jun 30, 2026 |
| Centene CorporationCNC | $32.9B | 22.6 | 0.2 | 1.5 | 12.0% | — | -0.1% | +1.9% | 6.6% | -2.35 | Q3 FY2026, Sep 30, 2026 |
| ResMed Inc.RMD | $32.8B | 20.6 | 5.7 | 5.5 | 4.9% | 1.1% | 29.6% | +5.9% | 26.8% | -0.36 | Q1 FY2027, Sep 30, 2026 |
| DexComDXCM | $31.6B | 31.9 | 6.2 | 12.5 | 3.5% | — | 20.5% | +11.2% | 39.1% | — | Q3 FY2026, Sep 30, 2026 |
| Medline Inc. Class A common stockMDLN* | $29.0B | — | — | 2.5 | — | — | — | +11.6% | — | — | Q2 FY2026, Jun 27, 2026 |
| Labcorp Holdings Inc.LH | $28.9B | 28.8 | 2.0 | 3.3 | 4.5% | 0.8% | 6.9% | +6.9% | 11.3% | 2.26 | Q3 FY2026, Sep 30, 2026 |
| West Pharmaceutical Services, Inc.WST | $28.4B | 44.5 | 8.4 | 9.6 | 1.6% | 0.2% | 24.5% | +8.7% | 21.5% | -0.27 | Q3 FY2026, Sep 30, 2026 |
| Quest Diagnostics Inc.DGX | $27.6B | 24.4 | 2.3 | 3.6 | 5.0% | 1.3% | 10.1% | +10.0% | 14.8% | 2.06 | Q3 FY2026, Sep 30, 2026 |
| Roivant Sciences Ltd. Common SharesROIV | $25.9B | — | 3441.9 | 6.1 | -3.2% | — | -13164.8% | −33.5% | -6.3% | — | Q1 FY2027, Jun 30, 2026 |
| United Therapeutics CorpUTHR | $25.6B | 19.5 | 8.1 | 4.0 | 4.3% | — | 42.5% | −1.9% | 20.5% | — | Q2 FY2026, Jun 30, 2026 |
| Incyte Genomics IncINCY | $24.5B | 60.6 | 4.1 | 4.3 | — | — | -50.4% | +14.0% | 7.2% | — | Q3 FY2026, Sep 30, 2026 |
| Insmed, Inc.INSM | $24.0B | — | 15.8 | 33.0 | -2.6% | — | -19.1% | +268.4% | -83.4% | — | Q3 FY2026, Sep 30, 2026 |
| Guardant Health, Inc. Common StockGH | $22.9B | — | 19.4 | — | -1.1% | — | -35.9% | +44.3% | — | — | Q2 FY2026, Jun 30, 2026 |
| STERIS plcSTE | $22.8B | 28.3 | 3.8 | 3.2 | 4.1% | 1.1% | 13.4% | +7.3% | 11.2% | 0.72 | Q1 FY2027, Jun 30, 2026 |
| Viatris Inc. Common StockVTRS | $21.4B | — | 1.5 | — | 9.1% | — | — | +5.0% | — | 3.95 | Q2 FY2026, Jun 30, 2026 |
| Tenet Healthcare Corporation NewTHC | $21.4B | — | 1.0 | 3.9 | 15.6% | — | — | +6.5% | — | — | Q3 FY2026, Sep 30, 2026 |
| Alnylam Pharmaceuticals, Inc.ALNY | $21.2B | 8.0 | — | 5.9 | — | — | 148.6% | +16.7% | 73.5% | — | Q3 FY2026, Sep 30, 2026 |
| Zimmer Biomet Holdings, Inc.ZBH | $18.6B | 23.0 | 2.2 | 1.5 | 8.2% | 1.0% | 9.1% | +4.8% | 6.4% | 2.54 | Q2 FY2026, Jun 30, 2026 |
| Medpace Holdings, Inc. Common StockMEDP | $18.1B | 35.0 | 6.4 | 31.0 | 3.7% | — | 19.2% | +8.5% | 88.5% | — | Q3 FY2026, Sep 30, 2026 |
| Exelixis IncEXEL | $17.1B | 19.3 | 6.8 | 9.3 | 6.8% | — | 33.1% | +10.2% | 48.3% | — | Q3 FY2026, Oct 2, 2026 |
| Revvity, Inc.RVTY | $16.9B | 71.2 | 5.8 | 2.3 | 3.3% | 0.2% | 7.1% | +1.3% | 3.3% | 2.09 | Q2 FY2026, Jul 5, 2026 |
| Solventum CorporationSOLV | $14.4B | 10.1 | 1.7 | 3.0 | -0.8% | — | 4.2% | +2.2% | 29.9% | 1.62 | Q2 FY2026, Jun 30, 2026 |
| Madrigal PharmaceuticalsMDGL | $10.0B | — | 7.8 | 19.0 | -2.1% | — | -15.9% | +71.2% | -62.1% | — | Q2 FY2026, Jun 30, 2026 |
A P/E or price to book is shown only where earnings or equity are positive. All sectors.
Method
- Aggregates
- the covered companies read as one company: sums of market value, earnings, revenue, equity and cash flow over the companies carrying both lines of a ratio, so a loss-maker lowers the market's P/E as it would in an index; a ratio with a non-positive denominator is withheld, so a sector's P/E has no reading while its trailing earnings are a loss in sum (the earnings yield, earnings over value, is shown negative instead).
- Medians
- the median company, over companies with a positive denominator (and, for P/E, positive trailing earnings).
- Point in time
- a week's value is the close on its last trading day times the shares on the newest quarterly filing first filed by that day; the earnings, revenue, equity and cash flow are that quarter's trailing twelve months, so a past reading uses only what had been filed.
- Shares
- the cover-page count on the filing, on today's split basis; where the cover line is blank (multi-class filers list each class separately) the quarter's diluted weighted count stands in; a count a thousandfold away from what the quarter's net income and diluted EPS imply was filed in the wrong unit and is put on the implied scale (60 companies: ABNB, ACN, AFRM, APP, ASTS, BLK, BMNR, CMCSA, CME, COIN, CPNG, CRCL, CRWV, CVNA, DASH, DDOG, DELL, EL, EXPE, F, FCNCA, FOXA, GOOGL, H, HEI, HOOD, IBKR, IOT, LAMR, LEN, MA, MDLN, META, MSTR, NET, NKE, NWS, OKTA, PLTR, QSR, RBLX, RBRK, RDDT, REGN, RIVN, RKT, RL, ROKU, RPRX, SHOP, SPG, TEAM, TOST, TSN, TW, UPS, VG, WDAY, XYZ, ZM).
- Quarters
- fiscal quarters are assigned to calendar quarters by their midpoint; a quarter is complete once at least 90% of the prior quarter's reporters have filed it.
- Growth
- each company's quarter against its own quarter a year earlier (nearest end to 365 days back, within 45 days), summed over the matched pairs; earnings growth is withheld when the year-ago sum is not positive.
- Margins
- gross margin is revenue less cost of revenue over revenue; banks and insurers report no revenue under the mapped concepts, so the Financial sector's margins cover its non-bank members.
- Leverage
- long-term debt less cash and equivalents, over trailing operating income plus depreciation and amortization; a company reporting long-term debt only in its 10-K carries that figure through the following three quarters.
- Survivorship
- the companies are today's, so the early years are the history of the firms that survived to be covered now, and the first weeks are dropped until coverage reaches half its peak.
- Market line
- S&P 500 (SPY) daily closes on the right-hand axis of every market chart, and each sector's own sector fund (XLB, XLC, XLY, XLP, XLE, XLF, XLV, XLI, XLRE, XLK, XLU), and an industry group its own (SMH), on its charts, from the market data mirror, so a reading can be seen against what the index or the sector was doing; a fund's line starts when it was listed.
531 companies, 458 with a trailing P/E at the latest close. Income statements, balance sheets and cash flows from each company's SEC 10-K and 10-Q filings (this site's extract); split-adjusted daily closes from a market data vendor. Every figure is computed from the filings; nothing here is a forecast or a recommendation.